Collegium Pharmaceutical Inc. (COLL)
NASDAQ:COLL
Want to see COLL full AI Analyst Report?
COLL Stock Chart & Stats
$34.41
$3.70(12.70%)
At close: 4:00 PM EST
$34.41
$3.70(12.70%)
Day’s Range― - ―
52-Week Range$28.34 - $50.79
Previous CloseN/A
Volume233.62K
Average Volume (3M)478.70K
Market Cap
$1.11B
Enterprise Value$1.64B
Total Cash (Recent Filing)$421.75M
Total Debt (Recent Filing)$808.06M
Price to Earnings (P/E)18.3
Beta0.48
Next Earnings
Jul 30, 2026EPS Estimate
1.72Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.37
Shares Outstanding32,433,780
10 Day Avg. Volume421,331
30 Day Avg. Volume478,699
Financial Highlights & Ratios
PEG Ratio-3.12
Price to Book (P/B)4.87
Price to Sales (P/S)1.88
P/FCF Ratio4.48
Enterprise Value/Market Cap1.49
Enterprise Value/Revenue2.07
Enterprise Value/Gross Profit3.40
Enterprise Value/Ebitda2.71
Forecast
1Y Price Target
$53.40Price Target Upside55.19% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)7.66
Revenue Forecast (FY)$872.42M
Bulls Say, Bears Say
Bulls Say
Acquisition Expands Product LineupAcquisition of AZSTARYS expands the ADHD franchise by adding a differentiated, established product with existing prescriptions, increasing long-term revenue visibility.
Balance Sheet StrengthStrong balance sheet flexibility and low leverage enhance capacity to pursue accretive strategic actions that can support growth and shareholder returns.
Commercial Synergies And ProfitabilityProjected commercial synergies and the ability to leverage an existing ADHD commercial infrastructure should improve margins and overall profitability.
Bears Say
Authorized Generic CompetitionAuthorized generic launches for flagship pain products increase competitive pressure on the pain franchise, raising the risk of sales erosion and margin compression.
Deal Valuation RiskDeal valuation appears elevated and may pressure returns if the new asset does not fully offset revenue declines from other products facing competition.
Limited Analyst InsightProvided analyst excerpt contains limited operational and financial takeaways, which reduces transparency and makes it harder for investors to assess the recommendation.
Collegium Pharmaceutical News
COLL FAQ
What was Collegium Pharmaceutical Inc.’s price range in the past 12 months?
Collegium Pharmaceutical Inc. lowest stock price was $28.34 and its highest was $50.79 in the past 12 months.
What is Collegium Pharmaceutical Inc.’s market cap?
Collegium Pharmaceutical Inc.’s market cap is $1.11B.
When is Collegium Pharmaceutical Inc.’s upcoming earnings report date?
Collegium Pharmaceutical Inc.’s upcoming earnings report date is Jul 30, 2026 which is in 67 days.
How were Collegium Pharmaceutical Inc.’s earnings last quarter?
Collegium Pharmaceutical Inc. released its earnings results on May 07, 2026. The company reported $1.76 earnings per share for the quarter, beating the consensus estimate of $1.524 by $0.236.
Is Collegium Pharmaceutical Inc. overvalued?
According to Wall Street analysts Collegium Pharmaceutical Inc.’s price is currently Undervalued.
Does Collegium Pharmaceutical Inc. pay dividends?
Collegium Pharmaceutical Inc. does not currently pay dividends.
What is Collegium Pharmaceutical Inc.’s EPS estimate?
Collegium Pharmaceutical Inc.’s EPS estimate is 1.72.
How many shares outstanding does Collegium Pharmaceutical Inc. have?
Collegium Pharmaceutical Inc. has 32,433,780 shares outstanding.
What happened to Collegium Pharmaceutical Inc.’s price movement after its last earnings report?
Collegium Pharmaceutical Inc. reported an EPS of $1.76 in its last earnings report, beating expectations of $1.524. Following the earnings report the stock price went up 7.724%.
Which hedge fund is a major shareholder of Collegium Pharmaceutical Inc.?
Currently, no hedge funds are holding shares in COLL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Collegium Pharmaceutical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$53.40 (55.19% Upside)
$53.40 (55.19% Upside)
Blogger Sentiment
Bullish
COLL Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 81.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $628.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 0.5%
Last 30 Days ▲ 0.5%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
18.21%
12-Months-Change
Fundamentals
Return on Equity
26.74%
Trailing 12-Months
Asset Growth
1.26%
Trailing 12-Months
Company Description
Collegium Pharmaceutical Inc.
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
COLL Company Deck
COLL Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed multiple clear commercial and financial positives: robust JORNAY prescription and revenue momentum, a durable pain portfolio, strong cash generation, and a strategic, accretive acquisition (AZSTARYS) that extends portfolio longevity and is expected to add revenue and synergies. Noted headwinds include higher operating expenses from deliberate commercial investments, generic/authorized generic dynamics for Nucynta, seasonal script pressure, and a temporary increase in leverage to fund the acquisition. Overall the company presented growth initiatives with supporting data and a plan to manage risks, and management reaffirmed guidance while outlining accretion and synergies from AZSTARYS.View all COLL earnings summariesCOLL Stock 12 Month Forecast
Average Price Target
$53.40
▲(55.19% Upside)
Technical Analysis
―
Pacira Pharmaceuticals
―
Supernus Pharmaceuticals
―
ANI Pharmaceuticals
―
Amphastar Pharmaceuticals
―
Ownership Overview
12.73% Insiders
32.75% Mutual Funds
16.59% Other Institutional Investors
9.21% Public Companies and
Individual Investors